+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report by Stage Type (Preclinical, Clinical, Commercial), Customer Type, Therapeutic Area, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 150 Pages
  • June 2024
  • Region: United States
  • Grand View Research
  • ID: 5983063
Description Jump to:
The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.17% from 2024 to 2030. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.

Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.

The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.

The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited’s Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.

U.S. Small Molecule Innovator API CDMO Market Report Highlights

  • Based on stage, the clinical segment led the market with the largest revenue share of 54.79% in 2023. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
  • Based on the customer type, the pharmaceutical segment held the market with the largest revenue share of 91.89% in 2023, attributing to rising funding for drug development is propelling segment growth
  • Based on therapeutic area, the oncology segment accounted for the largest revenue share of 42.05% in 2023. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
  • West Group dominated the U.S. market with the largest revenue share of 33.19% in 2023. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets


This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective - 1
1.10.2. Objective - 2
1.10.3. Objective - 3
1.10.4. Objective - 4
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. U.S. Small Molecule Innovator API CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Demand for Small Molecule Drugs
3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
3.2.1.3. Surge in Number of Clinical Trials
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.3. Technology Landscape
3.3.1. Integration Of AI in U.S. Small Molecule Innovator API CDMO Market
3.3.1.1. Current Dynamics and Future Trends
3.3.1.1.1. Drug Discovery and Design
3.3.1.1.2. AI-Assisted Drug API Synthesis
3.3.1.1.3. Process Optimization
3.3.1.1.4. Supply Chain Management
3.3.1.1.5. Clinical Trial Optimization
3.3.1.1.6. Regulatory Compliance
3.4. Total Number of Clinical Trials in U.S. (2021-2023)
3.4.1. Total Number of Clinical Trials by Phase (2021-2023)
3.4.2. Total Number of Clinical Trials by Therapeutic Area (2021-2023)
3.5. U.S. Small Molecule Innovator API CDMO Market: Regulatory Scenario /Framework
3.6. U.S. Small Molecule Innovator API CDMO Market: Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.7. Impact of COVID-19 on Small Molecule Innovator CDMO Market
3.8. COVID-19 Impact Analysis
Chapter 4. U.S. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
4.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.2. Phase I
4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.3. Phase II
4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.4. Phase III
4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Commercial
4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. U.S. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
5.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
5.3.1. Pharmaceutical
5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.2. Small
5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.3. Medium
5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.4. Large
5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Biotechnology
5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.2. Small
5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.3. Medium
5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.4. Large
5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. U.S. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis
6.1. Definitions and Scope
6.2. Therapeutic Area Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
6.5. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.5.1. Cardiovascular Diseases
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Oncology
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Respiratory Disorders
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Neurology
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Metabolic Disorders
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Infectious Diseases
6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Others
6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. U.S. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. Northeast
7.4.1. Market estimates and forecast, 2018-2030 (USD Million)
7.4.2. New Jersey
7.4.2.1. Competitive Scenario
7.4.2.2. Market estimates and forecast, 2018-2030 (USD Million)
7.4.3. New York
7.4.3.1. Competitive Scenario
7.4.3.2. Market estimates and forecast, 2018-2030 (USD Million)
7.5. Midwest
7.5.1. Market estimates and forecast, 2018-2030 (USD Million)
7.5.2. Illinois
7.5.2.1. Competitive Scenario
7.5.2.2. Market estimates and forecast, 2018-2030 (USD Million)
7.5.3. Missouri
7.5.3.1. Competitive Scenario
7.5.3.2. Market estimates and forecast, 2018-2030 (USD Million)
7.6. West Group
7.6.1. Market estimates and forecast, 2018-2030 (USD Million)
7.6.2. California
7.6.2.1. Competitive Scenario
7.6.2.2. Market estimates and forecast, 2018-2030 (USD Million)
7.6.3. Washington
7.6.3.1. Competitive Scenario
7.6.3.2. Market estimates and forecast, 2018-2030 (USD Million)
7.7. South
7.7.1. Market estimates and forecast, 2018-2030 (USD Million)
7.7.2. Texas
7.7.2.1. Competitive Scenario
7.7.2.2. Market estimates and forecast, 2018-2030 (USD Million)
7.7.3. Florida
7.7.3.1. Competitive Scenario
7.7.3.2. Market estimates and forecast, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Market Participant Categorization
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Lonza Group Ltd.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Novo Holdings (Catalent, Inc.)
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Siegfried Holding AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Recipharm AB
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. CordenPharma International
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Samsung Biologics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Labcorp
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Ajinomoto Bio-Pharma Services
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Piramal Pharma Solutions
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Jubilant Life Sciences (Jubilant Biosys Limited)
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. WuXi AppTec Co., Ltd.
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 Northeast Small Molecule Innovator API CDMO market, by States, 2018-2030 (USD Million)
Table 3 Northeast Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 4 Northeast Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 5 Northeast Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 6 New Jersey Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 7 New Jersey Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 8 New Jersey Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 9 New York Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 10 New York Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 11 New York Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 12 Midwest Small Molecule Innovator API CDMO market, by States, 2018-2030 (USD Million)
Table 13 Midwest Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 14 Midwest Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 15 Midwest Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 16 Illinois Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 17 Illinois Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 18 Illinois Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 19 Missouri Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 20 Missouri Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 21 Missouri Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 22 West Group Small Molecule Innovator API CDMO market, by States, 2018-2030 (USD Million)
Table 23 West Group Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 24 West Group Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 25 West Group Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 26 California Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 27 California Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 28 California Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 29 Washington Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 30 Washington Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 31 Washington Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 32 South Small Molecule Innovator API CDMO market, by States, 2018-2030 (USD Million)
Table 33 South Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 34 South Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 35 South Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 36 Texas Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 37 Texas Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 38 Texas Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
Table 39 Florida Small Molecule Innovator API CDMO market, by Stage Type, 2018-2030 (USD Million)
Table 40 Florida Small Molecule Innovator API CDMO market, by Customer Type, 2018-2030 (USD Million)
Table 41 Florida Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018-2030 (USD Million)
List of Figures
Figure 1 U.S. Small molecule innovator API CDMO market segmentation
Figure 2 Market research process
Figure 3 Information procurement
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Market formulation & validation
Figure 7 Commodity flow analysis
Figure 8 Value-Chain-Based Sizing & Forecasting
Figure 9 QFD model sizing & forecasting
Figure 10 Bottom-up approach
Figure 11 Market snapshot
Figure 12 Segment snapshot
Figure 13 Segment snapshot
Figure 14 Competitive landscape snapshot
Figure 15 Parent market outlook, 2023(USD Million)
Figure 16 Ancillary market outlook, 2023 (USD Million)
Figure 17 U.S. Small molecule innovator API CDMO market dynamics
Figure 18 FDA’s novel drug approvals in 2023
Figure 19 Percentage of clinical trials in U.S. by phase, clinical trials and therapeutics areas
Figure 20 Porter’s five forces analysis
Figure 21 U.S. Small molecule innovator API CDMO market: PESTEL analysis
Figure 22 U.S. Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
Figure 23 U.S. Small molecule innovator API CDMO market: Stage type movement analysis
Figure 24 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 25 Clinical small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 26 Phase I small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 27 Phase II small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 28 Phase III small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 29 Commercial small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 30 U.S. Small molecule innovator API CDMO market: Customer type outlook and key takeaways
Figure 31 U.S. Small molecule innovator API CDMO market: Customer type movement analysis
Figure 32 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 33 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 34 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 35 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 36 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 37 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 38 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 39 Large biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 40 U.S. Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
Figure 41 U.S. Small molecule innovator API CDMO market: Therapeutic area movement analysis
Figure 42 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 43 Oncology small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 44 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 45 Neurology small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 46 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 47 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 48 Others small molecule innovator API CDMO market estimates and forecast, 2018-2030 (USD Million)
Figure 49 U.S. Regional market: Key takeaways
Figure 50 U.S. Regional outlook, 2023 & 2030
Figure 51 U.S. Regional outlook, 2023 & 2030
Figure 52 Northeast small molecule innovator API CDMO market, 2018-2030 (USD Million)
Figure 53 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 New York small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 Midwest small molecule innovator API CDMO market, 2018-2030 (USD Million)
Figure 56 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 58 West Group small molecule innovator API CDMO market, 2018-2030 (USD Million)
Figure 59 California small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 60 Washington small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 61 South small molecule innovator API CDMO market, 2018-2030 (USD Million)
Figure 62 Texas small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 63 Florida small molecule innovator API CDMO market estimates and forecasts, 2018-2030 (USD Million)
Figure 64 Market participant categorization
Figure 65 Heat map analysis
Figure 66 Market participant categorization

Companies Mentioned

  • Lonza Group Ltd.
  • Novo Holdings (Catalent, Inc.)
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences (Jubilant Biosys Limited)
  • WuXi AppTec Co., Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages150
PublishedJune 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 8.2 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.6 Billion
Compound Annual Growth Rate6.1%
Regions CoveredUnited States
No. of Companies Mentioned12

Related Topics

Related Reports

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report by Product Type (Semi-Solid, Liquid), Service Type (Contract Development, Contract Manufacturing), Sponsors, Country, and Segment Forecasts, 2024-2030 - Product Image

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report by Product Type (Semi-Solid, Liquid), Service Type (Contract Development, Contract Manufacturing), Sponsors, Country, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • North America
From
Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 241 Pages
  • Global
From
Global Small Molecule Innovator API CDMO Market - Product Image

Global Small Molecule Innovator API CDMO Market

  • Report
  • 200 Pages
  • Global
From
Small Molecule Innovator CDMO Global Market Report 2024 - Product Image

Small Molecule Innovator CDMO Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029 - Product Image

Small Molecule Innovator CDMO Market - Forecasts from 2024 to 2029

  • Report
  • 152 Pages
  • Global
From

About the Small Molecule Innovator API CDMO Market

In the pharmaceutical industry, the Small Molecule Innovator Active Pharmaceutical Ingredient (API) Contract Development and Manufacturing Organization (CDMO) market encompasses a network of companies that provide a wide array of services for the development, manufacturing, and commercialization of small molecule APIs. Small molecules, traditionally the cornerstone of pharmaceutical offerings, are organic compounds with low molecular weight that can easily enter cells and alter biological processes. The Small Molecule API CDMOs offer expertise in chemistry, helping innovator companies to accelerate the drug development pipeline from initial conception through clinical trials to market launch. These services are pivotal for pharmaceutical companies that lack the requisite infrastructure or choose to outsource these functions to focus on core competencies such as drug discovery and marketing. The CDMO market is characterized by its versatile array of technologies, including custom synthesis, process optimization, scale-up, and regulatory compliance designed to meet the bespoke needs of innovator companies. Several prominent companies are operating within the Small Molecule Innovator API CDMO market, including Catalent, Lonza Group, Patheon (part of Thermo Fisher Scientific), Siegfried Holding AG, Cambrex Corporation, Wuxi AppTec, and Piramal Pharma Solutions. These organizations have established reputations for their technical capabilities, compliance track records, and supply chain reliability, making them vital partners in the pharmaceutical manufacturing landscape. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.